Registry for systemic treatments of alopecia areata
Systemic Treatments for Alopecia Areata Registry
This study is trying to see how well different systemic treatments work for people with moderate-to-severe alopecia areata, alopecia totalis, and alopecia universalis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 16 Years and up |
| Sex | All |
| Sponsor | Erasmus Medical Center Academic / other |
| Locations | 1 site (Rotterdam) |
| Trial ID | NCT06283316 on ClinicalTrials.gov |
What this trial studies
This multicenter prospective registry aims to assess the effectiveness, safety, and long-term outcomes of systemic treatments for alopecia areata, alopecia totalis, and alopecia universalis. It focuses on patients with moderate-to-severe forms of the condition who require more extensive therapies beyond localized treatments. By collecting real-world data on the utilization of these systemic therapies, the registry seeks to provide valuable insights that can inform evidence-based clinical management for affected patients.
Who should consider this trial
Good fit: Ideal candidates for this registry are individuals diagnosed with alopecia areata who are starting or currently using a systemic treatment.
Not a fit: Patients who are not proficient in the Dutch language or are unwilling to participate will not benefit from this registry.
Why it matters
Potential benefit: If successful, this registry could enhance the understanding of systemic treatments for alopecia areata, leading to improved patient care and management strategies.
How similar studies have performed: While there have been few randomized controlled trials on systemic treatments for alopecia areata, this registry approach is novel and aims to fill a significant gap in long-term data.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed with alopecia areata; * Starting/using a systemic treatment for alopecia areata; * Informed consent for registry participation obtained from patient and/or caretaker. Exclusion Criteria: * Not sufficiently capable of understanding the Dutch language; * Not willing to participate.
Where this trial is running
Rotterdam
- Erasmus University Medical Center — Rotterdam, Netherlands (Recruiting)
Study contacts
- Study coordinator: DirkJan Hijnen, MD, PhD
- Email: d.hijnen@erasmusmc.nl
- Phone: 0031 10 704 01 10
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.